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Background: Cervical cancer is the fourth most common cancer affecting women
worldwide. Since 2006, two human papillomavirus vaccines (HPVV) have been licensed
to protect women against the virus that causes cervical cancer. However, worldwide
coverage remains unequal. Studies from the USA found strong evidence for differences
in HPVV uptake by ethnicity and healthcare coverage. As the profile of ethnic groups
and the healthcare system in the USA differ from countries in Europe where HPVV is
free in most of the countries, we conducted a systematic review in order to analyze the
determinants of HPVV uptake in Europe.
Methods: We performed a systematic Pubmed, Scopus, and Science Direct search
to find articles published from HPVV availability in European countries until April 2014.
No age restriction was applied. We included all studies assessing factors associated
with HPVV uptake. Uptake refers to either initiation and/or completion of the three dose
vaccination program.
Results: Out of the 23 eligible studies, 14 were retrospective reviews of data, six were
cross-sectional surveys, and three were prospective cohort studies. Higher HPVV uptake
was associated with ethnic majority populations, higher socio-economic status, regular
cervical screening participation by the mother, and having received previous childhood
vaccinations.
Conclusion: Since the vaccine is offered for free in most of the European countries, the
findings suggest that ethno-cultural and educational factors play an important role when
it comes to HPVV uptake. Girls who were undervaccinated had also a lower uptake of
standard childhood vaccines and mothers who were less likely to attend cervical cancer
screening. This may indicate that only few parents have specific concerns with HPVV,
and that preventive health care should seek ways to target these vulnerable groups.
Keywords: human papillomavirus, vaccine, uptake, determinants, Europe, inequalities
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Introduction
The latest statistics published by the International Agency for
Research on Cancer (IARC), the specialized cancer agency of the
World Health Organization, shows that cervical cancer occupies
the fourth position in the list of the most common cancers affect-
ing women all over the world, preceded by breast, colorectal, and
lung cancers (1). More specifically, the estimated incidence of
cervical cancer was of 527,624 new cases in 2012. In the same year,
cervical cancer was responsible for 265,653 deaths in the world,
which constituted the fourth most common cause of cancer death
worldwide (1).
Cervical cancer is often defined as a disease of disparity,
because it differently affects poor and wealthy countries: at least
80% of cervical cancer deaths occur in developing countries (1).
However, disparities also occur within a single country, as is the
case of the USA, where Hispanic and African American women
have, respectively, 2 and 1.5 times more risk of developing cancer
than non-Hispanic White women (2). In Europe, the incidence
and mortality rates of cervical cancer vary considerably within
the region (3).
Since 2006, two human papillomavirus vaccines (HPVV) have
been licensed globally, aimed at preventing cervical cancer: Cer-
varix®, a bivalent vaccine that targets papillomavirus 16 and 18,
and Gardasil®, which additionally targets papillomavirus 6 and 11.
Types 16 and 18 are responsible for around 70% of all cervical
cancer cases, whereas types 6 and 11 are responsible for about
90% of anogenital warts (4). Immunization as a three-dose series
against the human papillomavirus (especially before sexual onset)
is recommended as primary prevention method of certain HPV
infections, in order to reduce the incidence of cervical cancer
and other anogenital cancer (5). However, worldwide coverage
remains unequal and uptake varies widely (6).
Population-based studies (7) reporting information about
HPVV uptake are helpful to identify determinants associated with
poor vaccination. Hence, vaccination programs or campaigns
geared toward reaching populations with low HPVV uptake can
be designed to improve coverage.
A systematic review and meta-analysis (8) published in Febru-
ary 2013 found strong evidence for differences inHPVV initiation
by factors such as ethnicity and healthcare coverage. The results
were based on 27 studies, of which the majority were performed
in the USA (n= 22), with additional studies from Canada (n= 2),
and only three were conducted in Europe. As the healthcare
system and the profile of ethnic groups in the USA significantly
differ from countries in Europe, we consider it relevant to focus
on studies reporting data from Europe. To our knowledge, no
systematic review reporting factors associated with HPV vaccine
uptake has been published to date in this specific region.
The aim of this study is to conduct a systematic review of the
peer-reviewed literature in order to analyze the determinants of
HPVV uptake in Europe.
Method
Data Sources
The PRISMA guidelines (9) have been followed throughout the
elaboration of this systematic review. A systematic Pubmed,
Scopus, and Science Direct search was performed by the authors.
The search terms were “HPV” or “human papillomavirus”
AND “vaccine” or “immunization” AND “uptake” or “coverage”
AND “inequalities,” “determinants,” “socio-economics,” “minority
groups,” “ethnicity,” or “social background.” Those terms were also
combined with “Europe,” “Eastern Europe,” “Russia.” Finally, the
reference lists of the selected articles were reviewed in order to get
additional references not identified via the database search.
Eligibility Criteria
We selected articles reporting HPVV uptake in females with no
age restriction, and reporting at least one factor associated with
vaccine uptake (either initiation, completion, or both). Articles
could include register data or data from questionnaires/surveys,
and no publication date filter was selected. All studies aimed at
identifying and assessing factors associated with HPVV uptake
were included.HPVVuptake by both routine and catch-up groups
was considered. No European country was excluded. Only articles
reported in English were selected. Interviews, reviews, and gray
literature were excluded. Articles in which the main focus was
knowledge, attitudes, or intentions to receive the HPV vaccine
were also not eligible. Publications reporting the same cohorts
were only included if the variables studied were different.
Definitions
Human Papillomavirus vaccines program initiation refers to the
uptake of either the first or the second dose of the three dose
program recommended to get the full benefit of the vaccine.
Human Papillomavirus vaccines program completion refers to
the reception of the three vaccine doses recommended to get full
protection.
The routine group refers to the primary target group to receive
the HPVV, which usually aims at girls that did not start their
sexual life (5). Catch-up programs refer to those programs that
have been created to target slightly older girls, usually up to the
age of 26. The recommended age for either routine or catch-up
group is determined by each country.
Data Extraction
All the relevant data were organized and extracted into the
PRISMA predefined form (9). Descriptive data such as study
population, study location, study time period, study design, vac-
cine delivery mechanism, and sample size were extracted for
each study. The overall risk of bias was assessed for each study
according to the sample size, and classified to be from low to high
risk (<1,000 participants). (Table 1).
Most of the studies reported their results based on tests for
associations between variables and the following assessment of the
strength of the associations. The effect measures most commonly
employed were: odds-ratio (n= 14), relative risk (n= 2), and
hazard ratio (n= 2). Other studies (n= 5) reported correlation
coefficients and p-values to measure association, which also were
included in the results section.
Data Variables and Statistical Analysis
The data analysis was performed by tabulating the data collected
from the variables of interest and outcomes (HPVV uptake, either
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initiation, completion, or both) of the selected studies. If available,
adjusted results were preferred to do the comparison among stud-
ies; however, unadjusted results were also considered in case no
adjustment was performed in the study.
Results
A total of 349 articles were identified through the different
databases. Of these, 221 were excluded for different reasons: hav-
ing a different research question (n= 98), not being European-
based studies (n= 79), being duplicates (n= 42), or not being
in English (n= 2). The abstracts of the remaining 128 articles
were reviewed, and 68 were excluded for not being a study
based in Europe (n= 46), for being review articles (n= 6), for
addressing a different research question (n= 6), for not reporting
data collected through registers or surveys (n= 4), for explaining
intentions and attitudes toward HPVV, not actual vaccination
(n= 3), for not reporting data on factors associated to HPV vac-
cine uptake (n= 2), and for not reporting data on HPV vaccine
uptake (n= 1). Overall, 60 full-text studies were assessed. After
assessing the inclusion and exclusion criteria, 19 were identified as
relevant articles for the systematic review and 41 were discarded.
The reasons for exclusion were reporting about intentions, beliefs,
or attitudes toward HPVV (n= 19), for not reporting data on
original European studies (n= 11), for not reporting data on
factors associated to HPV vaccine uptake (n= 9), and finally
for not providing data regarding HPV vaccine uptake (n= 2).
Additionally, four studies were found through the reference list of
some of the selected articles and included in our systematic review.
Overall, 23 articles reporting HPV vaccine uptake and factors
associated to it were selected since they fulfilled the inclusion
criteria (Figure 1).
FIGURE 1 | Flow chart of study selection procedure.
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Study Characteristics
Overall, data on 6,247,077 women aged from 12 to 44 years were
included in the studies presented in 23 articles, representing ten
countries. Of the included studies, 11 focused on the HPVV
initiation (10, 12–14, 18, 19, 21–23, 28, 31) and factors associated
with it, three focused on HPVV completion (11, 25, 27), and nine
focused on both initiation and completion (15–17, 20, 24, 26, 29,
30, 32), along with factors associated with it. Sample size ranged
from 238 to 2,493,698 women, and 19 studies had a sample size
over 1,000. The included studies were mostly retrospective chart
reviews or retrospective cohort studies based on data extracted
from registers or databases (n= 14). The rest were cross-sectional
surveys (n= 6) and prospective cohort studies (n= 3).
Factors Associated with Vaccine Initiation
Ethnicity
Overall, 12 studies (10, 12, 17, 19–24, 28, 31, 32) comparedHPVV
initiation by ethnicity. Nine (10, 12, 17, 20–24, 32) found an
association between ethnicity and HPVV initiation, where the
uptake was substantially lower in areas with high ethnic minority
populations. Out of the nine, three studies (20, 23, 24) conducted
in the UK showed that the probability of Non-white girls being
vaccinated was lower compared toWhite girls. The last study (32)
conducted in the Netherlands found that having Moroccan eth-
nicity contributed to non-participation in the HPV immunization
program compared with the ethnic majority in that country. That
was confirmed by another study conducted in the Netherlands
(32). On the contrary, three studies (19, 28, 31) [two of them (19,
28) with a very small sample size] found no association of HPVV
initiation with ethnic background (Table 2).
Socio-Economic Status and Education Level
Fourteen articles (10, 13–15, 17, 20–24, 26, 29, 31, 32) reported
data on socio-economic status or area-level indicators and HPV
vaccine initiation. All studies (10, 13–15, 21–24, 26, 29, 32) but
three (17, 20, 31) showed an association between pertaining to a
disadvantaged socio-economic group and lower HPVV initiation.
For two of these studies (22, 24), however, this association was
only seen for those girls that belong to the catch-up group (17–18
and 14–16 years, respectively). On the contrary, three studies (17,
20, 31) found no evidence of association betweenHPVV initiation
and socio-economic status. Regarding education level as such,
a small study (19) found that girls with more than 11 years of
school education had a higher HPVV initiation than those with
less than 11 years of education. These results were supported by
another study (14) that found that girls enrolled in a high school
or higher degree had higher vaccine initiation than those with a
lower degree (Table 3).
Age
Of the seven studies including a cohort of girls aged 12–24 years
(10, 13, 16–18, 26, 28), which allowed comparison of HPVV initi-
ation between different ages, three showed the highest vaccination
initiation at the age of 16–18 years (13, 16, 28), two (10, 17) at
the age of 14–15 years, one (18) at the age of 14–16 years, and
one (26) showed similar HPVV initiation from 12–17 years of
age. Additionally, two studies including a cohort of girls aged
18–26 years (14, 19) found no significant association between age
and HPVV initiation (Table 4).
Vaccination History
Having received, previous childhood immunization was associ-
ated with higher HPVV initiation in all studies (10, 12, 20, 23)
that compared immunization initiation by childhood vaccination
history, but one small study (28). Being vaccinated against Hep-
atitis B was found to be associated with higher HPVV initiation in
one study (18) (see Table S1 in Supplementary Material).
Mother’s Cervical Screening Attendance
Regular participation of mother in cervical cancer screening pro-
grams was positively associated with HPVV initiation in four
studies (18, 30–32) that compared uptake by mother’s screening
attendance. In one of the studies (32), the likelihood of HPVV
initiation was 40% higher if the mother regularly participated
in cervical cancer screening programs compared to those whose
mothers did not participate (see Table S2 in Supplementary
Material).
Area of Residence
One Danish study (12) making reference to population
density showed that girls living in the least urbanized
areas (1–9 inhabitants/km2) had the lowest HPVV initiation
(aHR= 0.87; 95% CI: 0.77–0.97) compared to the most urbanized
areas (>1,000 inhabitants/km2). HPVV initiation in urban
schools was twice that of rural schools (aOR= 1.9; 95% CI:
0.86–0.99) in another study (29) conducted in France. This was
supported by another study also conducted in France (15), which
found an association between living in a rural area and having a
lower HPVV initiation (aOR= 0.96; 95% CI: 0.92–0.99). On the
contrary, living in rural areas (<1,000 inhabitants/km2) remained
associated with higher vaccine initiation in two other studies
conducted in the Netherlands [aOR= 0.80; 95% CI: 0.70–1.00 for
a high degree of urbanization (31) and 6.6%; 95% CI: 6.10–7.00
for the other study (32)]. This result means that looking at the
participation in HPV immunization programs and cervical
cancer screening, 6.6% of non-participation in both prevention
programs was attributed to the fact that they were living in an
urban area (32).
Consultation with a Specialist or Physician’s
Recommendation
Having consulted with a specialist (pediatrician, family physician,
gynecologist, or other) was associated with higher vaccination
initiation in one study (aRR= 1.33; 95% CI: 1.30–1.36) (15) and
physician’s vaccine recommendation was associated with HPVV
initiation in another study (29) (aOR= 2.8; 95% CI: 1.70–4.70).
Other Factors
One study showed a lower uptake for those girls who never had
sexual intercourse in the past (OR= 0.44; 95% CI: 0.17–1.11)
(19), whereas the other revealed that having had sex in the past
is a negative predictor of HPVV initiation (aOR= 0.80; 95% CI:
0.60–1.00) (31).
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TABLE 2 | Ethnic background as a determinant of HPVV initiation and completion.
Authors Initiation Completion
Routine group Catch-up group Routine group Catch-up group
OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI
Rondy et al. (10)a, b (OR) Netherlands–Netherlands 1 (Ref.) NR NR NR
Netherlands–Surinamc 0.83 (0.71–0.97)
Netherlands–Turkeyc 0.78 (0.64–0.97)
Netherlands–Moroccod 0.55 (0.43–0.72)
Surinam–Surinamc 0.83 (0.75–0.93)
Turkey–Turkeyd 0.61 (0.56–0.66)
Morocco–Moroccod 0.33 (0.31–0.37)
Widgren et al.(12)e (HR) Danish-born w both parents Danish-born 1 (Ref.) NR NR NR
Danish-born w one parent Danish-born 0.84 (0.79–0.89)
Danish-born w none of parents Danish-born 1.02 (0.98–1.06)
EU/EFTA country. non-Danish 0.74 (0.67–0.82)
Blödt et al. (19) (OR) No migration background NSf NR NR NR
Migration background
Fisher et al. (20)g (OR) White British 1 (Ref.) NR 1 (Ref.) NR
Mixed ethnicity 0.94 (0.55–1.61)h NS
Asian or British Asian 0.59 (0.44–0.80)i NS
Black or British Black 0.50 (0.32–0.79)i NS
Chinese and other 0.48 (0.33–0.71)j NS
Non-stated 0.44 (0.39–0.50)j 0.77 (0.65–0.92)i
Kumar et al. (22) White NRk NRk NR NR
Asian
Black
Other
Roberts et al. (23)l (OR) White 1 (Ref.) NR NR NR
Other 0.72 (0.52–0.99)c
Spencer AM et al. (24)j, m (OR) White 1 (Ref.) 1 (Ref.) NS 1 (Ref.)
Mixed 0.73 (0.53–1.02) 1.28 (0.94–1.75) 0.51 (0.33–0.79)
Asian 0.90 (0.88–0.92) 0.95 (0.93–0.97) 1.06 (1.02–1.09)
Black 0.85 (0.77–0.94) 0.79 (0.71–0.85) 1.05 (0.91–1.21)
Other 0.65 (0.51–0.83) 0.70 (0.56–0.89) 0.72 (0.52–1.00)
Stöcker et al. (28) (OR) No migration background NS NR NR NR
Migration background
Mollers et al. (31) (OR) Dutch NS NR NR NR
Non-Dutch
Brabin et al. (21) British NRo NR NR NR
Ethnic minorities
Steens et al. (32) (OR) Dutch 1 (Ref.) NR NR NR
Moroccan 6.6% (6.1–7.0)n
Ganry et al. (17) NRp NR NRq NR
NR, not reported.
aCountry of birth of parents.
bAdjusted on implementation aspects and dates of vaccination.
cp-value <0.05.
dp-value <0.0001.
eAdjusted for place of residence (area), urban/rural (population density), place of origin, age of mother, and number of siblings.
fResults: 44 vs. 70% (HPVV uptake by girls with migration background vs. girls without migration background); x2=4.44; p=0.04.
gAdjusted for ethnicity, deprivation quintile, primary care trust (PCT)/local authority, program year, and educational setting.
hNS, non-significant.
ip-value <0.005.
jp-value <0.001.
kAssociation between ethnicity and HPVV uptake: final regression results: r2=0.25 for the routine group and r2=0.08 for the catch-up group.
lAdjusted for index of deprivation score (ID score).
mAdjusted for PCT (primary care trust) level and IMD (index of multiple deprivation).
nAbout 6.6% of non-participation in cervical cancer screening and HPV immunization was attributed to the fact that the girls had Maroccan ethnicity compared to Dutch girls.
oThe results show a significant lower HPVV uptake in schools with a high number of girls belonging to ethnic minorities in the UK (p-value <0.001 for trend).
pNegative correlation between HPVV initiation and rate of immigrants (r2=0.06; p-value=0.007).
qNegative correlation between HPVV completion and rate of immigrants (r2=0.1; p-value <0.001).
The results are reported as OR (95% CI), HR (95% CI), or RR (95% CI).
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TABLE 3 | Socio-economic status (SES) and education level as a determinant of HPVV initiation and completion.
Authors Definitions of SES OR/HR/RR 95% CI
Initiation
Mollers et al.
(31) (OR)
SES is defined as the average income per household in a
given postcode area with percentage of households with low
income, without a paid job, and with low average education.
That results in a score range. The lower the score, the higher
the socio-economic status.
NSa
Giambi et al.
(14)b (OR)
Employment status divided in three groups:
Unemployed, housewife, other (reference)
Employed
Student
1 (Ref.)
1.12 (0.76–1.63)
1.64 (1.13–2.37)
Education level divided in two groups:
Primary or middle school degree (reference)
High school degree
1 (Ref.)
1.41 (1.02–1.93)
Brabin et al. (21) Schools with high proportion of girls entitled to free
school meals (FSM)
NRc
Kumar et al. (22) Material deprivation was measured following the Index of
Multiple Deprivation (IMD) of 2007
NRd
Rondy et al.
(10)e (OR)
SES: defined as the average income per household in a given
postcode area with percentage of households with low
income, without a paid job, and with low average education.
That results in a score range. The lower the score, the higher
the socio-economic status
Results from a multilevel analysis:
SES (score n 1 vs. n): 1.05 (1.03–1.06)f
Lefevere et al.
(13) (HR)
The median income of the neighborhood where the girls
live in is divided in quintiles: quintile 1 to quintile 5 (from the
most to the least deprived areas)
Quintile 1: 0.75 (0.72–0.77)
Quintile 2: 0.93 (0.90–0.95)
Quintile 3: 1 (Ref.)
Quintile 4: 1.04 (1.02–1.07)
Quintile 5: 1.10 (1.07–1.12)
Right to preferential treatment (No-reference/Yes): it
means that the group with the right to preferential treatment
pays lower copayments. It depends on whether the
household income is below a certain threshold
1 (Ref.)
0.55 (0.52–0.58)
Roberts et al.
(23)f, g (OR)
Deprivation: lower super output areas (LSOA) and the
corresponding Index of Deprivation 2007 were obtained. The
sample was divided by quintiles (2). Quintile 1 (most deprived)
to Quintile 5 (least deprived)
Index of multiple deprivation
Per 10-point increase: 0.80 (0.85–0.95)
Ganry et al. (17) Socio-economic status was calculated through “the
median income per consumption unit and the percentage of
taxable households” (20)
NSh
Steens et al.
(32)i (OR)
SES is defined as the average income per household in a
given postcode area with percentage of households with low
income, without a paid job, and with low average education.
That results in a score range. The lower the score, the higher
the socio-economic status
Results from multilevel analysis:
Area with low SES: 7.6% (7–8.2%)
Area with moderate–low SES: 6.4%
(5.5–7.3%)
Blödt et al. (19)
(OR)
Education level: years of school education:
<11 years/11 years (ref.)
0.45 (0.20–1.02)
1 (Ref.)
Completion
Hughes et al.
(25)
SES is divided in groups of areas according to deprivation
level: Q1 (most deprived) to Q5 (least deprived)
NRj
Initiation and
completion
Lions et al.(15)k
(RR)
CMU beneficiary (No/Yes)
Usually, the 65% of the total HPV vaccine price is reimbursed
by the Social Security in France. But for patients covered by
the complementary social welfare healthcare program (CMU)
(an indicator of lower socio-economic status), 100% vaccine
of the price is reimbursed
Initiation:
1 (Ref.)
0.71 (0.68–0.75)
Completion:
1 (Ref.)
0.78 (0.76–0.81)
Fisher et al. (20)
(OR)
Deprivation: “postcodes from individual records were linked
to the corresponding lower super output areas (LSOA) and
deprivation score was assigned using the Index of Multiple
Deprivation of 2010, and the sample analyzed as quintiles”
(20). Quintile 1 (most deprived) to Quintile 5 (least deprived)
Initiation:
NSl
Completion:
NSl
(Continued)
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TABLE 3 | Continued
Authors Definitions of SES OR/HR/RR 95% CI
Sinka et al.
(26) (OR)
Results based on the association of each vaccination record
to a Scottish Index of Multiple Deprivation (SIMD) quintile,
which uses the postcode of residence. SIMD1= the most
and SIMD5= the least deprived areas
Initiation:
1 (most
deprived) – (Ref.);
1.25 (1.14–1.36);
1.39 (1.27–1.53);
1.59 (1.44–1.75);
1.80 (1.63–1.99)
(least deprived)
Completion:
1 (most
deprived) – (Ref.);
1.28 (1.20–1.37);
1.54 (1.43–1.65);
1.83 (1.70–1.97);
2.15 (1.99–2.31)
(least deprived)
FSM: % of girls eligible for free school meals at school.
FSM-1 (least) to FSM-5 (most)
Initiation:
1 (least) – (Ref.);
1.07 (0.80–1.43);
1.32 (0.99–1.77);
0.98 (0.73–1.31);
0.80 (0.61–1.04)
(most)
Completion:
1 (least) – (Ref.);
1.03 (0.80–1.32);
1.16 (0.90–1.49);
0.80 (0.62–1.04);
0.75 (0.60–0.94)
(most)
Bertaut et al.
(29)m (OR)
Parents SES are divided into three categories according to
family income:
Under-privileged (ref.)
Medium
Privileged
Initiation:
mother SESn:
1 (Ref.);
1.5 (1.1–2.1);
1.6 (1.1–2.4)
Father SESo:
1 (Ref.);
1.4 (0.8–2.2);
1.7 (1.3–2.2)
Completion:
mother SES:
NS;
Father SESp:
1 (Ref.);
0.8 (0.4–1.4);
0.4 (0.2–0.8)
Spencer
et al. (24)o
(OR)
Deprivation is defined as “the Index of Multiple Deprivation
(IMD) 2010 associated with the LSOA derived from the
address postcode (24)”. “The deprivation indices derive from
a combination of measures of income, employment status,
disability, health, crime, education, barriers to housing and
services, and living environment from the UK census of
2010.” The results are given divided in quintiles. Quintile 1
(most deprived) to Quintile 5 (least deprived-reference) (24)
Initiation:
routine group:
NS
Catch-up group:
0.75 (0.63–0.88);
0.75 (0.65–0.88);
0.91 (0.78–1.01);
1.04 (0.89–1.21);
1 (Ref.)
Completion:
routine group:
0.75 (0.63–0.88);
0.75 (0.65–0.88);
0.91 (0.78–1.01);
1.04 (0.89–1.21);
1 (Ref.)
Catch-up group:
0.64 (0.57–0.71);
0.77 (0.70–0.86);
0.91 (0.82–1.01);
1.02 (0.91–1.13)
1 (Ref.)
ap-value=0.2.
bResults from a multivariate logistic regression model, where all variables with a p-value <0.10 in the univariate model were included.
cThe study shows that HPVV uptake was significantly lower in schools with a higher proportion of students entitled to FSM (p=0.029).
dResults not reported as OR/HR. Regression results for multiple deprivation show that deprivation was a salient factor for uptake [B= 2.76% ( 5.27 to  0.24); adjusted r2=0.08]
and fall in uptake [B=1.82% (0.28–3.35); adjusted r2=0.12] in the catch-up group.
eAdjusted on implementation aspects and dates of vaccination.
fp-value <0.0001.
gAdjusted for ethnicity.
hNo correlation was found between socio-economic factors and HPVV coverage (p=0.6 and p=0.8).
iThe results from a multivariable multilevel logistic regression analysis show that 7.6% of non-participation in cervical cancer screening and HPV immunization was attributed to the fact
that the girls lived in a neighborhood with a moderate-low SES compared to if these girls would have been living in a neighborhood with high SES.
jEstimation of HPV vaccine coverage by deprivation level. Results of the percentage vaccination coverage mean (95% CI) from the most deprived to the least: 26.5 (23.3–29.6), 33.3
(29.6–37.0), 35.4 (30.8–40.0), 43.9 (40.5–47.2), 41.7 (38.4–45.0), 37.4 (35.7–39.1). p-value for trend (Wald test) <0.001.
kResults from multivariate analysis.
lThe results were not significant in the multivariable model (p-value=0.48).
mResults adjusted for school status and school area.
np-value=0.019.
op-value <10 3.
pp-value <10 4.
The results are reported as OR (95% CI) or HR (95% CI).
Factors Associated with Vaccine
Completion
Ethnicity
Lower HPVV completion was observed among ethnic minorities
in the catch-up group in a study (24) that compared vaccine
completion in the routine and catch-up group by ethnicity. This
was supported by another study (17) that found a negative corre-
lation between having completed vaccination by ethnicminorities
(r2= 0.1; p< 0.001). Another study (20) also found an associa-
tion between belonging to an ethnic minority group and lower
HPVV completion, but in this case, only those girls belonging to
the ethnic category “non-stated” showed lower vaccine program
completion (aOR= 0.77; 95%CI: 0.65–0.92; p< 0.004). The study
defined the “Non-stated” category as a group consisting of either
children of populations that had missing ethnicity because they
were born outside the participating Primary Care Trust (PCT)
(e.g., immigrants), because parents did not want to reveal their
ethnicity prior to the child’s birth, or because parents did not
understand that specific question at the moment they were asked
(Table 2).
Socio-Economic Status
Four studies (15, 24–26) out of six (15, 20, 24–26, 29) reporting
information about the three-dose program completion and socio-
economic status showed an association between non-completion
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TABLE 4 | Age as a determinant of HPVV initiation and completion.
Outcome Age
<13 14–15 16 17–18 19–24 >25
Initiation
Rondy et al. (10)a (OR) 1.06 (1.03–108) 1.11 (1.09–1.14) Ref. NR NR NR
1.10 (1.08–1.12)
Lefevere et al. (13)b (HR) 0.23 (0.20–0.25) 0.61 (0.55–0.67) 4.32 (4.11–4.55) 11.74 (10.89–12.65) NR NR
0.21 (0.19–0.24) Ref. 19.39 (17.47–21.52) NR
0.37 (0.33–0.41)
Giambi et al. (14)c (OR) NR NR NR NR NS NS
Blödt S et al. (19)d (OR) NR NR NR NS NS NR
Stöcker et al. (28)e (OR) NR – – 2.19 per year of life (1.16–4.15) NR NR
Completion
Lions et al. (15)f (RR) NR NR Ref. 1.06 (1.02–1.10) NR NR
Donadiki et al. (27)g (OR) NR NR NR 1.24 (1.02–1.50) Ref. NR
Initiation
Rouzier et al. (16)h NR 18, 30% 32% 29, 26% 16, 8, 5, 4, 4% NR
Lutringer-Magnin et al. (18)i NR NR 68.2% 56.9% 18.7% NR
Sinka et al. (26)j 93.7% 94.6% 93.0, 48.5%* NR NR NR
Ganry et al. (17)k 0.3% 22.3, 25.8% 16.2% 13.6, 9.3% 5.2, 2.9, 1.8, 1.4, 1.1, 0%
Completion
Rouzier et al. (16)l NR NR NR 45.8, 34% NR NR
Ganry et al. (17)m NR 65.5, 43.1% NR NR NR NR
Sinka et al. (26)j 89.4% 89.9% 86.6, 31.8%* NR NR NR
NR, not reported/NS, non-significant.
aAge group: year of birth: 1994, 1995, 1996. Adjusted for implementation aspects and dates of vaccination.
bAge group: year of birth: 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996. Results from a Cox regression model.
cAge group: 18–24 years of age, 25–26 years of age. Not significant association between age an HPVV uptake after the multivariate logistic regression model.
dAge group: 18–20 years, 21–25 years. Results from the multivariate analysis.
eAge group: 14–18 years of age. 91.3% of the females were 15 years old or older. Girls that were vaccinated, were more likely to be older. p-value=0.02.
fAge group: <17 years of age, 17 years of age.
gAge group: 18–20 years of age, 21–26 years of age. Results from multivariate logistic regression.
hResults from correlation coefficients and p-values: maximum coverage rate at the age of 16. From 16 onward, coverage rate decreases (p< 0.001).
iMaximum HPVV initiation rate at the age of 14–16 years (68.2%), followed by 17–20 (56.9%) and 21–23 (18.7%). A backward logistic regression was performed with the group of girls
aged 14–18 years. Age was embedded in the multivariate analysis.
jHPVV uptake in Scotland in 2008. Age group: 12–13 years of age (routine cohort), 15–16 and 16–17 years of age (catch-up cohort: divided into those that are at school and those that
already left it*).
kAge group: 13–14* years of age (*routine), 15–23 years of age (catch-up).
lResults from correlation coefficients and p-values: Maximum completion rate under 18 years of age (p< 0.0001).
mAmong the older group (catch-up), those aged 15 years at the time of the first dose are more compliant than older girls.
and low socio-economic background. However, for one of these
studies (25), the negative association was only observed among
the oldest group of girls (aged 16 or older). In contrast, one
study (20) found no association between lower HPVV comple-
tion and deprivation (p= 0.48), and one study (29) showed that
after initiation of the vaccination program, girls who attended
private schools [aOR= 0.50 (95% CI: 0.40–0.80), p< 0.001] or
who belonged to families where the father has higher incomes
were less likely to complete the three-dose program. Girls with at
least one university-educated parent were more likely to be fully
vaccinated than those whose parents did not finish high school
[relative risk reduction (RRR)= 15.45; 95%CI: 14.65–16.30] (11).
The same trend was seen in another study (27), which also com-
pared vaccine completion between University and Technological
Educational Institute students, and the results showed a higher
program completion among University students (OR= 1.22; 95%
CI: 1.01–1.49) (Table 3).
Age
Two studies (15, 27) reporting vaccine completion by age group
showed that girls aged over 17 years were more likely to complete
the vaccination program compared to other groups of age. Two
other studies (16, 17), however, revealed that girls under 18 years
of age were more likely to complete it. More specifically, one of
these studies (17) showed higher program completion in girls aged
13–14 years. On the contrary, a study conducted in Scotland (26)
found high vaccine program completion among all girls in that
study, except from the group of girls aged 16–17 years that had
already left school, where the uptake was lower (Table 4).
Mother’s Cervical Screening Attendance
Two studies (30, 32) found positive associations between moth-
ers’ cervical screening attendance and girls’ program completion
[aOR= 2.2; 95% CI: 1.6–2.9, and aOR= 1.54; 95% CI: 1.51–1.57,
respectively] (see Table S2 in Supplementary Material).
Area of Residence
One study (15) reporting data on HPV vaccine completion by
rural/urban area showed a lower vaccine completion in girls
living in rural areas (RR= 0.92; 95% CI: 0.86–0.98) compared
to those living in urban areas, whereas another study (29) did
not find significant variation in the results by population areas
(p= 0.24).
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Prescriber
Two studies (15, 17) found an association between the special-
ization of the physician responsible for the vaccine prescription
and the completion of the vaccination program. While one study
(17) found that the program completion was higher if the pre-
scriber of the first dose was a pediatrician or a gynecologist com-
pared to a general practitioner [48.1, 44.7, and 38.3%, respectively
(p< 0.001)], another found that the highest program completion
was achieved if the prescriber was a family physician [(RR= 0.90;
95% CI: 0.86–0.94) for the gynecologist, and family physician
was the reference group] (15). A third study (16) found no sig-
nificant correlation between prescriber (general practitioner vs.
gynecologist) and HPVV program completion.
Discussion
Main Findings
Belonging to ethnic minority groups and having a disadvantaged
socio-economic status were associated with lower HPVV initia-
tion and completion in the majority of the studies. The highest
HPVV program initiation was observed at the age of 16–18 years
inmore than half of the studies. Consultation with a specialist was
associated with higher HPVV initiation. Regular cervical screen-
ing participation by the mother was associated with higher HPV
vaccine program initiation and completion. Having received pre-
vious childhood vaccinations was associated with higher HPVV
uptake.
Findings in Relation to Other Studies
Regarding ethnicity, there is an overall association between
belonging to an ethnic minority group and having a lower prob-
ability of HPVV uptake. That suggests that cultural factors con-
cerning sexually transmitted infections could be an important
issue in the HPV vaccine uptake. This result is similar to the
previous systematic reviewmostly based onAmerican studies that
showed lower likelihood to initiate HPVV program among ethnic
minority groups compared to the ethnic majority population (8).
Two of the three studies that did not report a significant differ-
ence in uptake between ethnic backgrounds had a population
sample inferior to 500 girls. Thus, the number of ethnic minority
girls participating in the study might not be large enough to be
representative.
Most of the studies showed an association between higher
deprivation level and lower HPVV program initiation and com-
pletion. This is especially relevant since women and girls with
low socio-economic status are at a special risk of developing
cervical cancer (33, 34). Taking into account that the HPVV is
offered for free in the majority of the European countries, the
lower uptake among deprived people is unlikely to be a result of
purely economic reasons. Studies (35–39) reporting data on social
inequalities in healthcare indicate lower healthcare participation
among socioeconomically deprived populations. This indicates
that the lower vaccine uptake among most deprived populations
might be explained by a combination of factors; parents and girls
may have a different perception on the importance of HPVV as
a preventive measure, parents and girls may not have received
information about the immunization program, or if received,
did not have the time to read it or the knowledge or language
skills to understand it (39, 40). Some of the studies (22, 24, 25)
measuring completion rates by socio-economic status, however,
showed lower immunization program completion only for the
catch-up group. In this case, the reason is likely to be the different
deliverymechanism employed for older girls. Themajority of girls
in the routine cohort received the vaccination at school, whereas
older girls are often sent to healthcare settings to receive the
vaccine. This can lead to a decrease in adherence to the three-
dose immunization schedule since the girls or the parents have
to arrange an appointment at the clinic instead of having arranged
it by the school and during normal school hours.
As referred by Koulova et al. (5) and Garnet et al. (41), it
is recommended to start the vaccination program at a younger
age and preferably before sexual onset in order to increase the
vaccine effectiveness. However, in the light of our results, older
adolescents have a higher probability to initiate and complete the
program. The highest vaccination initiation rate was seen at the
age of 16–18 years in four out of seven studies. These results are
comparable to those published in a systematic review (4), which
shows that higher vaccination rates were achieved among older
adolescents. According toDempsey et al. (42), one reason could be
the fact that parentsmight bemore likely to accept the vaccination
as the age of the daughter increases.
According to the literature (43, 44), parental attitudes toward
preventive measures often influence the decision-making of their
daughters. This suggests that parents’ general perceptions toward
vaccinations may play a role also with regard to the uptake
of HPVV. Furthermore, regular mothers’ screening attendance
has been found to be associated with HPVV program initiation
and completion in a variety of studies in the literature (45–47).
This suggests that mothers who attend preventive health services
acknowledge their relevance, and may transmit these positive
attitudes to their daughters or to decisions regarding their daugh-
ters, which positively contributes to a high HPVV uptake. It is a
concern that non-attending cervical screening is a predictor for
under-vaccination, which suggests that there may be less added
value of vaccination.
Limitations
There are several potential limitations. There is a risk of selection
bias, which was assessed in the different studies according to sam-
ple size and the presence or absence of adjustment for potential
confounders. Studies reporting data of small samples (<1,000
participants) were considered to be at moderate-to-high risk of
bias (Table 1). Studies were heterogeneous in the study design, in
the independent variables included, and in the definition of refer-
ence groups, making it difficult to compare results. Additionally,
vaccination coverage was reported by either caregivers, by reim-
bursement data, or by the people themselves, introducing a risk
of misclassification bias, recall bias, or response bias. Sampling
strategy also differed across studies, leading to a potential selection
bias. Some studies lacked statistical significance, given the small
size and given that no adjustment for potential confounders was
performed. Additionally, there was little consistency in the factors
controlled for in the analysis across studies, limiting potentially
the comparison of the study results. Most of the studies were
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performed in rather wealthy countries, and no study was found
from Central- or Eastern-Europe, where the majority of cervical
cancer cases occur, even though the vaccine is available in most of
the European countries.
Conclusion
We found an association between ethnicminority background and
disadvantaged socio-economic status and lower HPVV uptake in
Europe. Given that the vaccine is offered for free in most of the
European countries, the findings suggest that ethno-cultural and
educational factors may be important when it comes to HPVV
uptake. The fact that girls who are undervaccinated with HPVV
also have lower uptake of standard childhood vaccines and moth-
ers that are less likely to attend cervical cancer screening indicate
that the reasons for non-vaccination are related to a general lower
compliance with preventive health rather than specific concerns
aboutHPVV. Efforts should be put into providing vulnerable pop-
ulations with a targeted information on the vaccine, and health
interventions such as vaccination campaigns should specifically
target them to improve HPVV uptake.
Because higher effectiveness is achieved if the vaccine is admin-
istered prior to sexual onset, communication efforts should be
made to increase theHPVVacceptance among young adolescents.
Since some girls leave school early, and therefore do not take
part of the school vaccination programs, a reminder program can
be designed where a letter is sent to each of the girls missing any
dose, aimed at reaching the maximum HPVV program initiation
and completion.
Further similar studies in other European countries, especially
in Eastern and Central Europe, are needed to get a representative
population and to find determinants in the HPVV uptake in
these countries. The creation of patterns in the HPVV uptake
would allow targeting these populations in which the uptake is
significantly lower, with the ultimate objective of reducing the
cervical cancer burden.
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